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Abstract: Young Indian women may be at risk of poor bone health due to malnutrition. The aim of
this study was to examine the effects on bone metabolism of a nutritional supplement in women
aged 25 to 44. The nutritional supplement was a protein-rich beverage powder fortified with multi-
micronutrients including calcium (600 mg), vitamin D (400 IU), and vitamin K (55 mcg) per daily
serving, while a placebo supplement was low-protein non-fortified isocaloric beverage powder. This
6-month randomised, controlled trial showed favorable changes in bone turnover markers (decreased)
and calcium homeostasis; such changes in older adults have been associated with slowing of bone
loss and reduced fracture risk. For example, serum CTX decreased by about 30% and PINP by
about 20% as a result of the increase in calcium intake. There were also changes in the ratio of
carboxylated to undercarboxylated osteocalcin and such changes have been linked to a slowing of
bone loss in older subjects. For example, the ratio increased by about 60% after 3 months as a result
in the improvement in vitamin K status. Finally, there were improvements in the status of B vitamins,
and such changes have been associated with reductions in homocysteine, but it is uncertain whether
this would affect fracture risk. The product was generally well tolerated. This study shows the
nutritional supplement holds promise for improved bone health among young Indian women.
Keywords: osteoporosis; bone turnover markers; vitamin D; vitamin K; vitamin B6; vitamin B12; folate
1. Introduction
Young adults achieve peak bone mass around the age of 30 years. Adequate nutrition
is thought to be critical in attaining this. Young Indian women may suffer malnutrition
and therefore attain an inadequate peak bone mass. For example, they have a low dietary
intake of calcium and poor vitamin D status [1,2]. The consequence of these deficiencies is
likely to be low bone mineral density [3], and this may predispose to fracture risk in later
life. It is estimated that in India, 50 million people have either osteoporosis of low bone
mass [3] and among young Indian women 44% have osteopenia [3].
Bone turnover markers (BTM) may be used to assess bone health, and they are
particularly useful in clinical trials [4]; in the presence of low dietary calcium and vitamin
D, these markers are usually elevated. High levels of BTM are associated with higher
fracture risk in the older woman [5]. There is evidence that these markers may be higher
in Indians than in Western populations. The bone turnover markers recommended as
reference markers by the International Osteoporosis Foundation are PINP and CTX [6].
Clinical trials of calcium and vitamin D supplementation in young women from a
number of countries have shown that there is a consequent decrease in bone turnover
markers [7–9]. Similar trials on older women have shown benefits for fracture risk [10].
Micronutrients, including selenium, zinc, vitamin B12, vitamin K, and folic acid, may
play a role in the bone health of young women. Thus, a nutrient supplement that contained
all these components might result in an improvement in bone health. Vitamin K increases
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the ratio of carboxylated to undercarboxylated osteocalcin, and it also increased the amount
of protein specific to bone [11–13].
The aims of this study were to evaluate the nutritional status of young Indian women
by their dietary record and biochemical assessments and to examine the effect of a nu-
tritional supplement in a randomised controlled trial. The key conclusions were that
young Indian women are deficient in certain nutrients. A nutrient supplement improves
bone turnover and micronutrient status in some but not all nutrients tested in young
Indian women.
2. Materials and Methods
2.1. Design
This was a double-blind, randomised, single-centre, parallel group, controlled study,
conducted between May 2017 and January 2018 at B. J. Medical College and Sassoon
Hospital, Pune, India (ClinicalTrials.gov identifier: NCT03155269; study number: 207192).
Eligible subjects (25 to 45-year-old premenopausal Indian women) were randomly (1:1)
allocated to either the test group (protein-rich beverage powder fortified with multi-
micronutrients (MMN)) or the control group (low-protein non-fortified isocaloric beverage
powder). The composition of the two products can be seen in Table 1.
Table 1. Composition of supplements. ICMR: Indian Council of Medical Research; RDA 2010:






Amount per daily serving
(% RDA)
Amount per daily serving
Energy (Kcal) 1900 215.9 (11.4) 215.9
Carbohydrate (g)






Fat (g) 20 1.8 (9) 2 (max)
Protein (g) 55 9 (16.4) 3 (max)
Vitamin A (mcg) 600 198 (33)
Vitamin D2 (IU) 400 400 (100)
Vitamin K2 (mcg) 55 55 (100)
Vitamin E (mg) 10 2.5 (25)
Vitamin B1 (mg) 1 0.3 (33)
Vitamin B2 (mg) 1.1 1.1 (100)
Niacin (mg) 12 4 (33)
Vitamin B6 (mg) 2 2 (100)
Vitamin B12 (mcg) 1 1 (100)
Folic acid (mcg) 120 120 (100)
Vitamin C (mg) 40 40 (100)
Biotin (mcg) 30 9.9 (33)
Pantothenic acid (mg) 5 1.7 (34)
Calcium (mg) 600 600 (100)
Iodine (mcg) 150 49.5 (33)
Magnesium (mg) 310 72.6 (23.4)
Zinc (mg) 10 1.6 (16.2)
Selenium (mcg) 40 25.8 (64.5)
Potassium (mg) 3225 325 (10.1)
At the screening visit (Visit 1), subjects provided their written informed consent to
participate in the study. Demographics, medical history, current/concomitant medications,
general physical examinations, and vital signs were recorded. Height, weight, and body
mass index (BMI) were assessed using anthropometric measurements. Urine pregnancy
testing was carried out on all female subjects who were of childbearing potential. After
that, the subject’s eligibility was determined based on inclusion/exclusion criteria. Eligible
subjects were given a diary and weighing scale to record 7-day food intake.
Eligible subjects attended the clinical study site for the baseline visit (Visit 2: 7 to
10 days after the screening visit) and were asked to bring the completed 7-day diary for
assessment of dietary intake of calcium, protein, and other key micronutrients. At the
baseline visit, subjects were randomly allocated to receive either the test or the reference
product at a 1:1 ratio, which was stratified by age (Stratum 1: Age ≥25 years to <35 years;
Stratum 2: Age ≥35 years to ≤45 years). The study centre aimed to recruit a target ratio
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of 50% of subjects in the 25 to 35 years age band and 50% in the 35 to 45 years age band
with a minimum of 40% in either age band. The study product was dispensed per the
randomisation schedule, with the first dose being taken (orally) under the observation of
site staff.
The randomisation schedule was generated by the Biostatistics Department, GSK CH,
prior to the start of the study, using validated internal software (SAS, Marlow, UK). Subjects
were instructed to take the study product (30 g of powder made up in 200 mL water), twice
daily (morning and preferably in the evening) for a total of six months. Subjects attended
on-site visits at baseline and at four follow-up visits; visit 3: 1.5 months (45 ± 7 days from
baseline), visit 4: 3 months (90 ± 7 days), visit 5: 4.5 months (135 ± 7 days), and visit
6: 6 months (end of treatment: 180 days ± 7 days). Subjects were fasting at baseline,
month 3, and month 6 visits, and blood (12-h fasting) and spot urine samples were collected
at baseline, 3 months, and 6 months.
The study product was consumed under the observation of site staff during each visit
except for visit 1 and visit 6. The last dose had to be consumed the evening before the
month 6 visit. In between study visits, the subjects consumed the study product at home
and completed a product compliance diary. Random home visits were made by site staff to
ensure compliance of product consumption at home. At each visit, subjects were asked to
return sachets of study product (empty and unconsumed). Subjects were considered as
non-compliant if they consumed less than 80% of the total amount of the recommended
dose (for the entire study duration).
The study protocol was approved by the Institutional Ethics Committee. The study
was conducted in accordance with the ethical principles that are outlined in the Declaration
of Helsinki, the International Council for Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) and all applicable local Good
Clinical Practice (GCP) and regulations. Written informed consent was obtained from each
participant prior to the performance of any study-specific procedures.
2.2. Study Participants
Women aged 25 to 45 years (inclusive) having good general and mental health with no
clinically significant and relevant abnormalities in medical history or upon physical exami-
nation, and BMI between 18 and 30 kg/m2 (inclusive), were included in the study. Women
who had attained physiological menopause defined as those without a menstrual period
for 12 consecutive months, who were pregnant or were intending to become pregnant over
the duration of the study, and women who were breastfeeding were excluded from the
study. Women with current or regular use of any prescription, over-the-counter vitamin
supplements, or herbal medicine, treatment with bisphosphonates (any dose within the
previous 2 years) or other medications known to affect bone (within the previous 6 months);
history of metabolic bone disease; any hormonal disorders or disturbances; and bone frac-
ture in last 12 months and those who were having more than two units of alcohol per
day and/or were smoking were also excluded. Additionally, women who took any other
health food drinks/beverages or supplements or had been on supplements within a month
prior to study start, and women who used any medication that was known to influence
bone mass were excluded from the study. The use of calcium, vitamin D, and multivitamin
supplements on a regular basis were to be stopped 2 months before the onset of the trial.
2.3. Endpoints
The co-primary outcome variables were the changes from baseline after 6 months of
treatment in the bone resorption marker serum C-terminal cross-linking telopeptide of
type I collagen (s-CTX-I) and the bone formation marker expressed as ratio of carboxylated
osteocalcin to under carboxylated-osteocalcin (c-OC/uc-OC).
The secondary outcome variables were change from baseline after 3 and 6 months of
treatment in bone formation markers: serum N-terminal propeptide of type I procollagen
(s-PINP), bone alkaline phosphatase (BSAP), serum alkaline phosphatase (s-ALP) and
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c-OC/uc-OC (at 3 months); change from baseline after 3 and 6 months of treatment in
bone resorption markers urinary CTX-1, serum N-terminal telopeptide of type 1 collagen
(s-NTX-1), and serum CTX-1 (at 3 months); change from baseline after 3 and 6 months of
treatment in calcium status determined by serum calcium, parathyroid hormone (s-PTH),
and urinary calcium to creatinine ratio (Ca/CR). Finally, changes from baseline after 3 and
6 months of treatment in other bone metabolism parameters and micronutrients including
phosphorus, selenium, vitamin D, folate, vitamin B12, vitamin B6, and zinc were assessed.
Safety assessments included assessment of adverse events (AEs) and serious AEs
(SAEs). Other safety assessments included laboratory tests, vital signs, physical examina-
tion, and haemoglobin examination.
2.4. Laboratory Methods
The following laboratory tests were performed by enzyme-linked immunosorbent
assays: c-OC, ucOC (Takara Bio Inc, Shiga, Japan) and serum CTX (Immunodiagnostic
Systems, Boldon, UK), BSAP, serum folate, and vitamin B12. Calcium was measured by
spectrophotometry. Electrochemiluminescence methods were used for the measurement of
osteocalcin, chemiluminescence for PTH, enzyme-linked immunosorbent assay (ELISA),
for NTX and radioimmunoassay for intact PINP. Vitamin B6 and 25-D3 were measured by
liquid chromatography with tandem mass spectrometry (LC-MS-MS). Selenium and zinc
were measured by inductively-coupled plasma/mass spectrometry (ICP-MS). The tests
were performed after a 12-h fast, and the urine sample was a morning spot urine. The vol-
ume of blood on each visit was 57.5 mL, and the samples were stored at −70 degrees
Celsius until measurement.
2.5. Statistical Analysis
A sample size of 44 subjects per group was needed to provide 90% power to detect a
difference of −110 ng/L in s-CTX-1, assuming an SD of 144 based on α report by Kruger
et al. [7] and a two-tailed significance level of α = 0.025. To allow for a 20% dropout rate,
54 subjects (total 108) were randomised per treatment arm.
Similarly, 30 subjects per group were needed to provide 90% power to detect a 12.5 dif-
ference (test minus control group) in c-OC/uc-OC, assuming a standard deviation (SD)
of 13 based on the study by Binkley et al. [14] and a two-tailed significance level of α = 0.025.
To allow for a 20% dropout rate, a total of 36 participants (total = 72) were to be randomised
per treatment arm. However, as the sample size for the first primary endpoint was larger,
the overall sample size required for this study was 108 in total.
There were three analysis populations. Randomised subjects were all those subjects
who were randomised and might or might not have received the study product. The safety
population included all subjects who received at least one dose of the study product.
Assessment of efficacy was based on the intent-to-treat (ITT) population, which included
all subjects in the safety population who had at least one post product co-primary efficacy
assessment (either s-CTX-1 or c-OC/uc-OC).
The co-primary efficacy variables of the study were the change from baseline in bone
resorption marker (s-CTX-1) after 6 months and the change from baseline in c-OC/uc-OC
after 6 months. The efficacy variables were analysed using analyses of covariance (AN-
COVA) including the product group and age strata as fixed effects, and the corresponding
baseline value as the covariate. Adjusted means, within-product p-values for each product
group, product group difference expressed in percentage change from baseline, and the
between-product p-values based on the statistical model described above were calculated.
Statistical tests to compare treatments were two-sided and were employed at a level of
significance of α = 0.025 for the co-primary endpoints. Assumptions of normality and
homogeneity of variances in the ANCOVA model were evaluated after study unblinding.
If violations were observed, then either suitable data transformations were performed as a
post-hoc sensitivity analysis or a non-parametric Van Elteren test was used, and results
were to be compared with the primary analysis results. To visually inspect the treatment
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effect of s-CTX-1 and c-OC/uc-OC, plots across time (baseline, month 3, and month 6)
were displayed with least square (LS) means and ±SE bars, which were obtained from the
ANCOVA analysis.
As a post-hoc sensitivity analysis, s-CTX-1 was log transformed (natural logarithm),
and the log-transformed data were analysed using the ANCOVA model with the product
group and age strata as fixed effects, and the corresponding log transformed baseline
value as a covariate. The interpretation of the data was based on the geometric mean ratio,
95% confidence interval, and p-value.
A post-hoc subgroup ANCOVA analysis was performed on one of the co-primary
variables, s-CTX-1 by age strata using the ITT population. The ANCOVA model had
the product group, strata, and the product and strata interaction as fixed effects, and the
baseline value of s-CTX-1 as the covariate. Statistical tests to compare treatments were
two-sided and employed a level of significance of α = 0.05.
For the secondary efficacy analyses, a similar protocol was followed, using ANCOVA
as described above. The level of significance used was α = 0.05. A post-hoc sensitivity
analysis was performed using the following variables: urinary Ca/CR, vitamin D3 (us-
ing 25 OH D3), and plasma vitamin B6. These variables were log transformed (natural
logarithm) and the log-transformed data were analysed using the ANCOVA model with
product group and age strata as fixed effects, and the corresponding log transformed
baseline value as a covariate. The interpretation of the data was based on the geometric
mean ratio and p-value. The efficacy variable of serum folate was analysed using the
non-parametric Van Elteren test stratified by age, and the interpretation of data was based
on p-values obtained from this test. All analyses were performed in SAS 9.4 (SAS Institute
Inc., Cary, NC, USA).
3. Results
3.1. Demographics
A total of 117 subjects were screened for entry into the study; 114 subjects were
enrolled (n = 57 in each group), of which 102 (89.5%) completed the study (Figure 1).
Overall, the demographics and clinical characteristics were comparable between the
groups (Table 2). The mean (SD) age was 34.6 (4.60) years, with a range from 25 to 44 years.
Overall, 53 randomised subjects (46.5%) were in the age group of 25 to less than 35 years,
and 61 randomised subjects (53.5%) were in the age group of 35 to 45 years. Subjects had a
mean (SD) height of 153.4 (5.12) cm, body weight of 58.5 (7.89) kg, and BMI of 24.8 (2.90) kg/m2.
The number (%) of subjects compliant with the consumption of study products in the test
product group and the control group were 51 (98.1%) and 48 (96.0%), respectively.
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Figure 1. Consort diagram. ITT: intent-to-treat.
Table 2. Demographics, nutritional status, and baseline characteristics.
Test Control Reference Interval
General Characteristics
Female, n (%) 57 (100) 57 (100)
Age, years [mean (SD)] 35.0 (4.4) 34.2 (4.8)
Height, cm [mean (SD)] 152.8 (4.9) 154.1 (5.3)
Weight (kg) [mean (SD)] 57.5 (7.1) 59.6 (8.5)
Body mass index, kg/m2
[mean (SD)]




s-CTX-1 (ng/L) 435 (119) 440 (160) 111 to 791 [15]
c-OC/uc-OC 1.2 (0.7) 1.2 (0.8) 0.69 ± 0.41 [12]
Secondary endpoints
CTX-I/CR, mcg/mmol 2.6 (1.6) 2.4 (1.3) N/A
s-NTX-I (nM BCE/L) 11.5 (3.3) 11.9 (3.0) Female 6.2 to 19
s-PINP (mcg/L) 59.6 (21.6) 58.0 (22.2) 17.3 to 75.2 [15]
Osteocalcin (mcg/L) 19.8 (5.2) 19.3 (5.5) 7.0 to 38.0
ALP (IU/L) 67.8 (25.1) 69.8 (17.9) 20 to 125
BSAP (mcg/L) 10.9 (4.0) 10.7 (2.9) 4.7 to 18.8
s-PTH (pmol/L) 5.7 (2.8) 5.4 (3.0) 1.1 to 6.8
Calcium (mmol/L) 2.30 (0.06) 2.30 (0.07) 2.12 to 2.56
Phosphorus (mmol/L) 1.15 (0.13) 1.13 (0.14) 0.8 to 1.45
Urinary Ca/CR
(mmol/mol CR)
107.4(85.0) 107.7 (83.1) 28 to 905
25(OH)D3 (nmol/L) 43.2 (35.4) 41.6 (19.9) >50 [16]
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Table 2. Cont.
Test Control Reference Interval
Micronutrients, Mean (SD)
Selenium (mcmol/L) 1.34 (0.17) 1.31 (0.20) 0.83 to 2.03
Zinc (mcmol/L) 10.8 (1.7) 10.6 (2.0) 9.2 to 19.9
Folate (nmol/L) 18.5 (13.2) 36.5 (129.3) >12.3
Vitamin B6 (nmol/L) 23.4 (15.5) 21.8 (13.3) 8 to 88
Vitamin B12 (pmol/L) 174.8 (72.5) 206.8 (132.3) 148 to 812
s-CTX-1: serum cross-linked C-telopeptide of type I collagen; c-OC/uc-OC: ratio of carboxylated to under-carboxylated osteocalcin;
CTX1/CR: serum cross-linked C-telopeptide of type I collagen/creatinine ratio; s-NTX-1: serum N-terminal telopeptide of type I collagen; s-
PINP: serum procollagen type I N propeptide; ALP: alkaline phosphatase; s-PTH: serum parathyroid hormone; Ca/Cr: calcium-to-creatinine
ratio. The ranges were provided from the manufacturer unless stated otherwise.
3.2. Efficacy
3.2.1. Primary Efficacy Results
The primary endpoints used were the change in s-CTX-1 and c-OC/uc-OC over
6 months (Table 3). In both groups, there was a significant decrease (considered to be
associated with improved bone health) in s-CTX after 6 months of treatment (−33% at the
test group, and −23% at the control group, p < 0.001). Although the decrease was more
at the test group, i.e., favouring the test product, the between-group differences were not
significant at the 2.5% level (p-value 0.132).
Table 3. Changes in biochemistry in response to test and control products over six months—
primary endpoints.
Test (n = 52) Control (n = 50) Difference
s-CTX-1 (ng/L)
Baseline Mean (SD) 444 (119) 441 (162)
6 months Mean (SD) 283 (142) 324 (168)
% Change from
baseline, (SD)
−33 (41) *** −23 (34) *** NS
c-OC/uc-OC
Baseline Mean (SD) 1.21 (0.76) 1.14 (0.68)
6 months Mean (SD) 1.49 (0.67) 1.25 (0.49)
% Change from
baseline, (SD)
53 (82) *** 45 (134) NS
Analysis was performed using the analyses of covariance (ANCOVA) model with product group and age strata
as fixed effects, and the corresponding baseline value as covariate. Data are presented as adjusted mean. Note
that for CTX, a post-hoc analysis was performed as the underlying assumptions of normality, and homogeneity of
variance had a slight deviation from normality. This involved log-transforming the data, and the results are shown
in Table 4. s-CTX-1: serum cross-linked C-telopeptide of type I collagen; c-OC/uc-OC: ratio of carboxylated to
under-carboxylated osteocalcin; SD: standard deviation. p-values: *** < 0.001; NS: not significant.
A post-hoc analysis to assess the potential impact of age on the treatment effect was
performed. At month 6, the p-value for interaction between the product group and the
age strata was not statistically significant (p = 0.193) at the 5% level. Another post-hoc
analysis was performed as the underlying assumptions of normality and homogeneity
of variance had a slight deviation from normality. This involved log-transforming the
data. The between-group adjusted geometric mean ratio (test over the reference product)
favoured the test product but was not statistically significant at the 2.5% level (p = 0.121).
This is shown in Table 4.
There was a significant increase in c-OC/uc-OC after 6 months of treatment in the
test group (+53%, p < 0.001). The increase from baseline at the control group was not
significant (p-value 0.308). The between-group differences were not significant at the 2.5%
level (p-value 0.047).
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Table 4. Post-hoc tests for primary and secondary efficacy results that had deviations from the
assumption of normality.




3 months 0.84 0.043
6 months 0.85 0.121
Urinary Ca/Cr
3 months 1.52 0.014
6 months 0.73 0.242
Vitamin D3
3 months 0.84 0.003
6 months 0.90 0.308
Folate *
3 months NA <0.001
6 months NA <0.001
Vitamin B6
3 months 1.75 <0.001
6 months 1.60 <0.001
These variables were log transformed (natural logarithm), and the log-transformed data were analysed using
the ANCOVA model with product group and age strata as fixed effects, and the corresponding log-transformed
baseline value as a covariate. The interpretation of the data was based on the geometric mean ratio and p-value.
* The efficacy variable of serum folate was analysed using the non-parametric Van Elteren test stratified by
age, and the interpretation of data was based on p-values obtained from this test. s-CTX-1: serum cross-linked
C-telopeptide of type I collagen; Urinary Ca/Cr: urinary calcium-to-creatinine ratio; NS: not significant; NA: not
available. For s-CTX-1 at 6 months (primary efficacy result), the level of significance was at 2.5%, while for the
other parameters, the level was at 5%. The p-values shown in bold were statistically significant.
3.2.2. Secondary Efficacy Results—Bone Metabolism Parameters
All the results that involve parametric tests are summarised in the Table 5. The ad-
justed mean (± standard error) plots by time and treatment for s-CTX-1, c-OC/uc-OC,
s-PINP, and BSAP are shown in Figure 2. The results of the post-hoc analyses using
log-transformed data and non-parametric tests are shown in Table 4.




Baseline Mean (SD) 444 (119) 441 (162)
3 months Mean (SD) 300 (158) 330 (167)
% Change from baseline, (SD) −32 (37) *** −24 (28) *** NS
c-OC/uc-OC
Baseline Mean (SD) 1.21 (0.76) 1.14 (0.68)
3 months Mean (SD) 1.71 (1.21) 1.19 (0.83)
% Change from baseline, (SD) 67 (124) *** 23 (110) *




Baseline Mean (SD) 11.6 (3.4) 11.9 (3.1)
3 months Mean (SD) 10.7 (6.3) 10.0 (5.7)
% Change from baseline, (SD) −3.0 (58.5) −14.1 (50.4) * NS
6 months Mean (SD) 8.2 (3.1) 9.4 (4.2)
% Change from baseline (SD) −25.2 (33.3) *** −19.0 (32.3) *** NS
s-PINP (mcg/L)
Baseline Mean (SD) 59.6 (22.0) 58.7 (23.1)
3 months Mean (SD) 46.6 (18.0) 54.2 (21.0)
% Change from baseline, (SD) −19 (22) *** −4 (29) * **
6 months Mean (SD) 43.9 (14.2) 51.1 (23.0)
% Change from baseline, (SD) −21 (25) *** −9 (30) *** **
ALP (IU/L)
Baseline Mean (SD) 69.0 (26.0) 70.4 (18.4)
3 months Mean (SD) 63.3 (23.4) 67.7 (17.7)
% Change from baseline, (SD) −8 (11) *** −2 (13) *
6 months Mean (SD) 63.4 (20.3) 70.2 (17.0)
% Change from baseline, (SD) −5 (23) ** 1 (14) *
BSAP (mcg/L)
Baseline Mean (SD) 11.1 (4.1) 10.8 (3.1)
3 months Mean (SD) 9.4 (4.3) 10.2 (3.1)
% Change from baseline, (SD) −16 (20) *** −2 (38) * **
6 months Mean (SD) 10.0 (3.3) 11.8 (3.4)
% Change from baseline, (SD) −5 (35) * 10 (13) * ***
s-PTH (pmol/L)
Baseline Mean (SD) 5.7 (2.9) 5.3 (2.5)
3 months Mean (SD) 5.0 (3.4) 5.8 (2.6)
% Change from baseline, (SD) −6 (46) 16 (59) NS
6 months Mean (SD) 7.3 (3.4) 8.1 (4.3)
%Change from baseline, (SD) 43 (78) ** 70 (106) *** NS
Calcium (mmol/L)
Baseline Mean (SD) 2.30 (0.06) 2.30 (0.07)
3 months Mean (SD) 2.27 (0.08) 2.26 (0.09)
% Change from baseline, (SD) −2 (4) ** −2 (4) *** NS
6 months Mean (SD) 2.40 (0.08) 2.33 (0.08)
% Change from baseline, (SD) 3 (4) *** 1 (4) ** *
Phosphorus (mmol/L)
Baseline Mean (SD) 1.14 (0.13) 1.13 (0.14)
3 months Mean (SD) 1.16 (0.19) 1.18 (0.16)
% Change from baseline, (SD) 3 (18) 6 (15) ** NS
6 months Mean (SD) 1.13 (0.15) 1.12 (0.18)
% Change from baseline, (SD) 0 (15) 0 (16) NS
Analysis was performed using the ANCOVA model with product group and strata as fixed effects and the corresponding baseline value as
covariate. Data are presented as adjusted mean. Note that for CTX, a post-hoc analysis was performed as the underlying assumptions of
normality and homogeneity of variance had a slight deviation from normality. This involved log-transforming the data, and the results are
shown in Table 4. s-CTX-1: serum cross-linked C-telopeptide of type I collagen; c-OC/uc-OC: ratio of carboxylated to under-carboxylated
osteocalcin; CTX1/CR: serum cross-linked C-telopeptide of type I collagen/creatinine ratio; s-NTX-1: serum N-terminal telopeptide of
type I collagen; s-PINP: serum procollagen type I N propeptide; ALP: alkaline phosphatase; s-PTH: serum parathyroid hormone; Ca/Cr:
calcium-to-creatinine ratio; SD: standard deviation; p-values: *** < 0.001; ** 0.001–0.010; * 0.010–0.050; NS: not significant.











Figure 2. Adjusted mean (± standard error) plots by time and treatment (intent-to-treat (ITT)) population: n = 102.
(A): s-CTX-1; (B): c-OC/uc-OC ratio; (C): s-PINP; (D): BSAP.
The decrease in s-CTX-1 observed at 3 months in both groups was significant when
compared to baseline, but the between-group differences were not significant (p-value 0.181).
Once again, the post-hoc analysis to test the impact of treatment did not show a significant
interaction between the product group and the age strata at month 3 (p-value 0.691). The log
transformation post-hoc analysis resulted in a between-group adjusted geometric mean
ratio (test over reference product), which favoured the test product, and it was statistically
significant at the 5% level (p = 0.043). This is shown in Table 4.
Serum NTX-1, another bone resorption marker, showed a significant decrease at
6 months in both groups, but between-group differences were not significant (p-value 0.128).
In terms of bone formation markers, the increase observed in c-OC/uc-OC at 3 months
favoured the test group (+67% vs. +23%, p-value: 0.018). There was a decrease in s-PINP
in both groups at 3 and 6 months. The decrease was more pronounced, and thus more
favourable, at the test group (at 6 months −21% vs. −9%, p-value: 0.007). BSAP decreased
more at the test group at 3 months and 6 months (between-group differences at 3 and
6 months: p-values 0.004 and < 0.001, respectively).
When evaluating the calcium status, s-PTH increased significantly at both groups
at 6 months, with a more pronounced and thus less favourable increase observed at the
control group, but the between-group differences were not significant (p-value: 0.159).
Serum calcium increased slightly more at 6 months at the test group (between-group
difference p-value: 0.041), but both phosphorus and the urinary calcium to creatinine ratio
did not show any significant differences between groups, except when the data for the
urinary calcium to creatinine ratio were log transformed, there was a significant increase
for the test group at 3 months (Table 4).
3.2.3. Secondary Efficacy Results—Micronutrients
For selenium and zinc, the between-group differences at both 3 and 6 months were
not significant (Table 6).
For serum folate, the underlying assumption of normality and homogeneity of vari-
ance was examined during analysis, and significant deviations from normality were ob-
served. Normality was not achieved after log-transforming the data, so the non-parametric
Van Elteren test was performed as a post-hoc analysis. The between-group difference was
statistically significant at month 3 and at month 6 (p-value < 0.001). The median change
from baseline, which is robust to outliers, is indicative of an increase in the test group at
month 3 (+3.60 nmol/L or 19%) and at month 6 (+7.95 nmol/L or 42%).
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Baseline Mean (SD) 1.35 (0.17) 1.31 (0.18)
3 months Mean (SD) 1.29 (0.22) 1.25 (0.29)
% Change from
baseline, (SD)
−3 (19) −4 (20) ** NS
6 months Mean (SD) 1.41 (0.28) 1.35 (0.26)
% Change from
baseline, (SD)
5 (21) 4 (22) NS
Zinc (mcmol/L)
Baseline Mean (SD) 10.8 (1.7) 10.6 (2.1)
3 months Mean (SD) 10.3 (1.8) 10.0 (1.5)
% Change from
baseline, (SD)
−3 (17) −4 (21) ** NS
6 months Mean (SD) 10.3 (1.3) 10.0 (1.6)
% Change from
baseline, (SD)
−2 (17) −4 (20) ** NS
Vitamin B12
(pmol/L)
Baseline Mean (SD) 177.1 (75.1) 209.6 (140.3)
3 months Mean (SD) 212.4 (96.7) 190.2 (77.0)
% Change from
baseline, (SD)
22 (41) * −1 (27) *
6 months Mean (SD) 227.4 (95.4) 205.4 (92.0)
% Change from
baseline, (SD)
35 (51) ** 6 (30) NS
Analysis was performed using the ANCOVA model with product group and strata as fixed effects, and the
corresponding baseline value as the covariate. Data are presented as adjusted mean. SD: standard deviation;
p-values: ** 0.001–0.010; * 0.010–0.050; NS: not significant.
A post-hoc analysis was also performed for vitamin B6, as there was a slight deviation
from normality. At months 3 and 6, the between-group adjusted geometric mean ratio (test
over reference product) favoured the reference product (both statistically significant with
p-values < 0.0001).
Vitamin B12 did not show a significant difference between groups at months 6,
but there was a significant difference at month 3, favouring the test product (Table 6).
3.3. Safety
Overall, both supplements were well tolerated. No deaths, SAEs, or treatment emer-
gent adverse events (TEAEs) leading to premature discontinuation of the study product
were reported in any group. All the reported TEAEs were mild in intensity. A total of
19 (33.3%) subjects in each group reported at least one TEAE (Table 7). Of these, 14 subjects
from the test group and 12 subjects from the control group reported treatment-related
TEAEs (17 TEAEs in each group).
The most frequently reported TEAEs were gastrointestinal disorders, which were more
frequently reported in the test group, 11 subjects (19.3%) compared with seven subjects
(12.3%) in the control group. The most common (>5% in any group) TEAE was nausea
(test vs. control: 8.8% vs. 3.5%). Other infrequently occurring TEAEs were constipation,
dyspepsia, abdominal distension, flatulence, abdominal pain, abdominal pain (upper),
diarrhoea, and vomiting. There were no remarkable trends in haemoglobin, vital signs,
and physical examination within or between treatment groups.
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Table 7. Summary of adverse events—Safety population.
Adverse Events
Number (%) of Subjects [Events]
Test (n = 57) Control (n = 57)
Number of subjects with at least one adverse event 19 (33.3) [17] 19 (33.3) [18]
Nausea 5 (8.8) [5] 2 (3.5) [2]
Constipation 1 (1.8) [1] 2 (3.5) [2]
Dyspepsia 1 (1.8) [1] 2 (3.5) [2]
Abdominal distension 1 (1.8) [1] 1 (1.8) [1]
Abdominal pain 2 (3.5) [2] 0
Flatulence 1 (1.8) [1] 1 (1.8) [1]
Abdominal pain upper 0 1 (1.8) [1]
Diarrhoea 0 1 (1.8) [1]
Vomiting 1 (1.8) [1] 0
Serum parathyroid hormone increased 2 (3.5) [2] 7 (12.3) [7]
Urine calcium/creatinine ratio increased 3 (5.3) [3] 6 (10.5) [6]
Vitamin D deficiency 7 (12.3) [7] 2 (3.5) [2]
Vitamin B12 deficiency 0 1 (1.8) [1]
Dysgeusia 0 1 (1.8) [1]
Headache 1 (1.8) [1] 0
Hunger 1 (1.8) [1] 0
4. Discussion
4.1. Bone Turnover Markers and Bone Metabolism
The rationale for selecting CTX-I as the co-primary endpoint was that in older women,
a high level of this marker is associated with an increase in fracture risk [19]. In addition,
when an anti-resorptive drug is used in osteoporosis, the greater the reduction in CTX-I,
the greater the reduction in the risk of fracture, particularly vertebral fracture [20]. The test
product did cause a significant decrease in CTX-I of over 30%, and this is in line with
other clinical trials of calcium supplementation in younger women. For example, in New
Zealand women given 1000 mg daily for 16 weeks [7], CTX-I decreased by 39% and in
British women given up to 676 mg daily for 4 weeks, CTX decreased by 20% [9]. The finding
that was unusual in this study was that the control group also had a decrease in CTX,
although at 3 months, this was less marked than in the test group. The administration
of the extra calories (216 kCal daily) may have caused weight gain, and such changes
can result in decreases in bone resorption [21]. An alternative explanation is that bone
resorption markers show large variability, and so, this might explain these unexpected
changes. The other bone resorption marker (serum NTX) showed a similar pattern of
change to CTX.
The changes in bone formation markers were quite different to those in bone resorption
markers. PINP is the bone formation marker recommended by the IOF/IFCC [6]. As for
CTX, when an anti-resorptive drug is used in osteoporosis, the greater the reduction in
PINP, the greater the reduction in the risk of fracture, particularly vertebral fracture [20].
The test product did cause a significant decrease in PINP of 20%, and this is in line with
other clinical trials of calcium supplementation in younger women. For example, in New
Zealand women given 1000 mg daily for 16 weeks [7], PINP decreased by about 20%.
The changes in BSAP were slightly lower, being around 5% in this study. The changes
in bone formation markers did differ between the test and control groups in contrast to
bone resorption markers. They do tend to be more responsive to repletion with vitamin D
than bone resorption markers. In this study, the baseline 25 hydroxy vitamin D (25-OHD)
levels were on average well below the level of sufficiency (50 nmol/L) [16]. However, the
supplement of vitamin D used in this study was vitamin D2, but the assay was for vitamin
D3, so we cannot know the effect of the supplement on 25-OHD2 levels.
Supplementation with calcium and vitamin D might be expected to increase serum
and urinary calcium and to decrease parathyroid hormone levels. There was a significant
3% increase in serum calcium at 6 months and a significant 52% increase in urinary calcium
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to creatinine ratio at 3 months (based on the ratio of the geometric means). The changes
in PTH were unexpected, with increases in both groups. There is evidence from trials
of calcium supplements with or without vitamin D that bone loss and fractures can be
prevented in older people [10,22,23]
4.2. Vitamin K Status
The rationale for measuring the ratio of carboxylated to undercarboxylated OC was
that it is a marker of vitamin K status. The mean level at baseline in both groups was higher
than that reported by others, indicating some degree of deficiency of vitamin K [14,24,25].
Vitamin K is essential for the gamma-carboxylation of bone proteins, including those
present in bone (such as OC, matrix Gla-protein, and protein S). As changes in uc-OC and
c-OC are in opposite directions, their ratio reflects an estimate of vitamin K nutrition [12].
A clinical trial of a commonly used form of vitamin K2 (namely MK-7, at a dose of 375
mcg daily for 1 year) prevented bone loss, particularly trabecular bone [24]. Furthermore,
a meta-analysis of randomised controlled trials indicated that vitamin K2 administration
reduces uc-OC and increases c-OC, and it is associated with reduced bone loss and possibly
a reduction in the risk of fractures [13]. The dose of 55 mcg of MK-7 given in this study
had a significant benefit (increase) at 3 months but not at 6 months.
4.3. Other Micronutrients
Vitamins B12, B6, and folic acid are cofactors in homocysteine metabolism, and sup-
plementation with B vitamins is effective in lowering homocysteine levels in humans [26].
High homocysteine levels have been associated with an increase in the risk of fracture,
including hip fracture [27]. One large clinical trial did not show any effect of vitamin B
supplementation on fracture risk [26].
Following 6 months’ supplementation with 2 mg vitamin B6, there was an adjusted
mean increase of 9 nmol/L in the test group (resulting in a similar level to that found in US
adults), indicating satisfactory supplementation. The mean baseline plasma vitamin B6
in the test group (23.6 nmol/L, Table 2) was below the mean level of 32 nmol/L among
US adults (aged between 21 and 44 years) and close to the threshold for deficiency of
20 nmol/L [17].
The threshold for vitamin B12 deficiency is 148 pmol/L, and the mean baseline
B12 in the test group was 177 pmol/L. Following 1 mcg daily supplementation (the UK
recommends 1.5 mcg vitamin B12 daily [18]), mean serum vitamin B12 in the test group
increased by 50 pmol/L at 6 months (an increase of 35%). There were significant increases
in serum folate (Table 4) based on non-parametric analyses. Whether these changes in B
vitamins would have an effect on fracture risk remains unknown.
5. Conclusions
This randomised controlled 6-month trial of a nutritional supplement showed favor-
able changes in bone turnover markers (decreased) and calcium homeostasis; such changes
in older adults have been associated with slowing of bone loss and reduced fracture risk.
There were also changes in the ratio of carboxylated to undercarboxylated osteocalcin (as a
result in the improvement in vitamin K status), and such changes have been linked to
slowing of bone loss in older subjects. Finally, there were improvements in the status of B
vitamin, and such changes have been associated with reductions in homocysteine, but it is
uncertain whether this would affect fracture risk. The product was generally well tolerated.
This study shows the nutritional supplement holds promise for improved bone health
among young Indian women. The next step may be a trial with bone mineral density as
the endpoint.
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